Centessa Pharmaceuticals (CNTA)
(Delayed Data from NSDQ)
$9.16 USD
-0.13 (-1.40%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $9.16 0.00 (0.00%) 5:02 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CNTA 9.16 -0.13(-1.40%)
Will CNTA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CNTA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CNTA
The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics
What Awaits These 4 Drug Stocks That More Than Doubled in 2023?
CNTA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) Have the Potential to Rally 40.85% as Wall Street Analysts Expect?
Wall Street Analysts Predict a 35.92% Upside in Centessa Pharmaceuticals PLC Sponsored ADR (CNTA): Here's What You Should Know
Centessa (CNTA) Surges 72% in the Past 3 Months: Here's Why
Other News for CNTA
Centessa 10.81M share Spot Secondary priced at $9.25
Centessa Pharmaceuticals prices $100M ADS offering
Wall Street Analysts Are Bullish on Top Healthcare Picks
Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares